PML and type 2 diabetes mellitus: Immunogenicity of MYL-1501D was assessed in the phase 3 noninferiority studies INSTRIDE 1 (NCT02227862) and INSTRIDE 2 (NCT02227875), which compared the safety and efficacy of MYL-1501D and reference insulin glargine in patients with type 1 and type 2 diabetes, respectively.